My Medical Gateway Blog

The NHS is under sustained pressure where it matters most: high-volume orthopaedic procedures that directly affect mobility, independence and the ability to work. Knee, hip, shoulder, spine and ACL treatments sit at the centre of this challenge. The data shows long waits, high private costs and limited domestic capacity. It also shows something else: immediate, high-quality and more cost-effective availability across Europe.

The conversation around NHS waiting lists is often broad and unfocused. In reality, the pressure is highly concentrated. A small number of procedures account for a disproportionate share of both demand and delay. MMG’s analysis identifies five core treatments as the primary pressure points: total knee replacement, total hip replacement, shoulder replacement, spinal surgery and ACL reconstruction.

These are not niche procedures. They are the backbone of elective orthopaedic care in the UK.

Take knee replacement as the clearest example. There are currently over 49,000 patients on NHS waiting lists, with an average wait of nearly 29 weeks. Annual procedure volumes are high, with over 79,000 carried out by the NHS and – for the first time ever – a further 80,000 in the private sector, which has now overtaken the NHS. Yet despite this scale, demand continues to outstrip capacity.

Hip replacement follows a similar pattern. Over 31,000 patients are waiting, with the same average delay of around 28.7 weeks. More than 100,000 procedures are performed annually by the NHS alone. The system is active, but it is not keeping pace.

Shoulder replacement, while lower in volume, still faces delays of 20 to 30 weeks depending on the Trust. Spinal procedures and ACL reconstruction present a different profile, often affecting younger, working-age patients where the impact of delay is not just medical but economic. ACL waits in particular can extend to 40–60 weeks in many parts of the country. 

The common thread is clear: sustained backlog, long waiting times and high patient urgency. The UK private sector is often seen as the release valve for this pressure. In practice, it is constrained. It represents only a small proportion of total healthcare capacity and is closely intertwined with the NHS. As a result, it cannot absorb demand at scale, and pricing reflects that limitation.

This is where the European market becomes relevant. Across all five core treatments, there is a consistent and material price differential between the UK and EU private sectors. A total knee replacement averages €15,304 in the UK compared to €8,723 in the EU. A total hip replacement is €14,611 versus €8,328. Shoulder replacement stands at €13,048 in the UK compared to €7,437 in Europe. 

Spinal procedures show an even wider gap. A discectomy averages €13,089 in the UK against €7,461 in the EU. ACL repair, while lower in absolute terms, still shows a clear difference at €7,591 in the UK compared to €4,327 in Europe. 

These are not marginal savings. They are typically in the range of 30 to 50 percent. The critical point – as we have explained in earlier blogs – is that this price differential does not reflect a compromise on quality. It reflects structural differences in how healthcare systems operate. European private hospitals function at greater scale, within mixed insurance systems that allow for higher throughput, better utilisation of facilities and more competitive pricing.

Many of these hospitals are also more clinically complete environments, with integrated emergency capabilities and broader in-house specialisms than are commonly found in UK private facilities.

This creates a clear opportunity. MMG is not attempting to replace the NHS or compete with it. The objective is more targeted and practical: to help relieve pressure on the system by redirecting self-pay patients who are willing and able to seek immediate treatment abroad.

These are patients who would otherwise remain on NHS waiting lists or enter an already constrained and costly UK private market. By enabling them to access world-class treatment in Europe, capacity is freed up domestically while patients receive faster care.

The focus on the five core orthopaedic treatments is deliberate. These procedures combine high demand, long waiting times and a clear economic impact on patients’ lives. They are also where the European capacity and pricing advantage is most evident. MMG’s role is to make this pathway viable.

The platform brings together accredited hospitals that meet strict clinical and operational standards, ensuring that quality is not a variable in the decision. It standardises treatment packages, pricing and patient pathways, allowing for direct comparison and informed choice.

It is also important to be clear about positioning. MMG is not targeting the lowest-cost segment of the market. There are cheaper options available, particularly in areas such as cosmetic surgery. That is not the objective.

The focus is on certainty. Patients using MMG are making time-sensitive decisions to restore mobility, return to work and resume normal life. They require confidence in clinical outcomes, clarity on pricing and immediate access to treatment. Cost matters, but only within that framework.

The combination of NHS backlog, constrained UK private capacity and scalable European supply creates a structural imbalance. That imbalance is not temporary. What is new is the ability to address it in a systematic way.

For the five core treatments driving the NHS backlog, the solution is no longer theoretical. The capacity exists. The quality is established. The price advantage is clear.

MMG exists to connect those dots, and in doing so, to provide a practical release valve for one of the most persistent pressures in UK healthcare.